Clinical Stage Immuno-Oncology player, Imugene Limited (ASX:IMU) has revealed the outcome of the HER-Vaxx Phase 2 IDMC (Independent Data Monitoring Committee) meeting. The Company notified that IDMC has confirmed HER-Vaxx safety and recommended continuation of study without modification.
In addition, Imugene informed that the patients receiving HER-Vaxx cancer immunotherapy are responding actively. To recall, the Company is continuing with HER-Vaxx Phase 2 clinical trial involving 68 HER-2+ metastatic gastric cancer patients.
IMU is currently trading at $0.026 as at 11:46 AM AEST on 4th May 2020.